Dr. Creelan Discusses Results of MEDI4736 in Combination With Gefitinib in NSCLC

Published: Monday, Jun 01, 2015



Ben Creelan, MD, medical oncologist with Moffitt Cancer Center, discusses the results from a phase I study of MEDI4736, an anti-PD-L1 antibody, in combination with gefitinib, an EGFR inhibitor, in patients with non-small-cell lung cancer (NSCLC).

Despite several new promising inhibitors against EGFR, many EGRF-mutant NSCLC patients still eventually develop resistance. Anti-PD-L1 antibodies offer a potential solution to this resistance, says Creelan. In a phase I dose escalation trial, the combination of gefitinib and MEDI4736 was found to be an effective and tolerable therapy. A maximum tolerated dose was not reached, and no dose limiting toxicities were observed.

Gefitinib is not approved in the United States, but it is already indicated across 80 markets worldwide. An approval in the United States is expected soon, says Creelan. The regulatory future for MEDI4736 is not yet fully defined.

<<< View more from the 2015 ASCO Annual Meeting



Ben Creelan, MD, medical oncologist with Moffitt Cancer Center, discusses the results from a phase I study of MEDI4736, an anti-PD-L1 antibody, in combination with gefitinib, an EGFR inhibitor, in patients with non-small-cell lung cancer (NSCLC).

Despite several new promising inhibitors against EGFR, many EGRF-mutant NSCLC patients still eventually develop resistance. Anti-PD-L1 antibodies offer a potential solution to this resistance, says Creelan. In a phase I dose escalation trial, the combination of gefitinib and MEDI4736 was found to be an effective and tolerable therapy. A maximum tolerated dose was not reached, and no dose limiting toxicities were observed.

Gefitinib is not approved in the United States, but it is already indicated across 80 markets worldwide. An approval in the United States is expected soon, says Creelan. The regulatory future for MEDI4736 is not yet fully defined.

<<< View more from the 2015 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x